Pyrazinamide (PZA) is a significant anti-tuberculosis
drug, with its powerful sterilizing activity, in fighting tuberculosis, a
disease caused by Mycobacterium
tuberculosis. When activated into pyrazinoic acid by the bacterial enzyme
pyrazinamidase, a specific and important macrophage enzyme is inhibited, which
contributes to pyrazinamide’s antimycobacterial activity and prevention of macrophage necrosis. This enzyme is also the target of several
drugs, so that the host-modulating effects of pyrazinamide can be obtained with
these compounds, and this is independent of pyrazinamide drug resistance.
Researchers at the University of New Mexico have
developed a novel method for the treatment of tuberculosis, especially
pyrazinamide resistant disease. The present invention also allows for discovery
of new TB drugs acting on such targets.
STC has filed intellectual property on this exciting new technology and
is currently exploring commercialization options. If you are interested
in information about this or other technologies, please contact Arlene
Mirabal at email@example.com or 505-272-7886.